GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rosetta Genomics Ltd (OTCPK:ROSGQ) » Definitions » Net Income (Continuing Operations)

Rosetta Genomics (Rosetta Genomics) Net Income (Continuing Operations) : $-9.95 Mil (TTM As of Jun. 2017)


View and export this data going back to 2007. Start your Free Trial

What is Rosetta Genomics Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Rosetta Genomics's Net Income (Continuing Operations) for the three months ended in Jun. 2017 was $-1.14 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2017 was $-9.95 Mil.

Rosetta Genomics Net Income (Continuing Operations) Historical Data

The historical data trend for Rosetta Genomics's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rosetta Genomics Net Income (Continuing Operations) Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.70 -13.17 -14.53 -17.35 -16.23

Rosetta Genomics Quarterly Data
Dec10 Mar11 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.04 -3.26 -3.97 -4.84 -1.14

Rosetta Genomics Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.95 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rosetta Genomics  (OTCPK:ROSGQ) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Rosetta Genomics Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Rosetta Genomics's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Rosetta Genomics (Rosetta Genomics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rosetta Genomics Ltd (OTCPK:ROSGQ) » Definitions » Net Income (Continuing Operations)
Comparable Companies
BOM:526504 TSXV:MBI.H TEAR TSXV:AVCR NGM:LIFE B BOM:526546 BOM:541299 ASX:CTE TSXV:TELO ASX:LSH IDTA XSAT:ALPH BOM:526301 ABMC XLRM WAR:BMX XKRX:271850 WAR:IGN BOM:516110 SGX:505
Traded in Other Exchanges
N/A
Address
10 Plaut Street, Science Park, Rehovot, ISR, 76706
Website
http://www.rosettagenomics.com
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.
Executives
Sabby Management, Llc 10 percent owner 115 HIDDEN HILLS DR, SPICEWOOD TX 78669
Sabby Healthcare Volatility Master Fund, Ltd. 10 percent owner C/O SABBY MANAGEMENT, LLC, 10 MOUNTAINVIEW ROAD, SUITE 205, UPPER SADDLE RIVER NJ 07458